Infliximab Preferentially Induces Clinical Remission and Mucosal Healing in Short Course Crohn's Disease with Luminal Lesions through Balancing Abnormal Immune Response in Gut Mucosa
This study was undertaken to evaluate the efficacy of infliximab (IFX) in treatment of Crohn's disease (CD) patients. 106 CD patients were undergoing treatment with IFX from five hospitals in Shanghai, China. Clinical remission to IFX induction therapy was defined as Crohn's disease activi...
Saved in:
Main Authors: | Lijuan Yu (Author), Xuehua Yang (Author), Lu Xia (Author), Jie Zhong (Author), Wensong Ge (Author), Jianxin Wu (Author), Hongchun Liu (Author), Fei Liu (Author), Zhanju Liu (Author) |
---|---|
Format: | Book |
Published: |
Hindawi Limited,
2015-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Optimising infliximab induction dosing to achieve clinical remission in Chinese patients with Crohn's disease
by: Kouzhu Zhu, et al.
Published: (2024) -
ADALIMUMAB INDUCTION AND MAINTAINING REMISSION FOR CROHN'S DISEASE IN PATIENT WHO LOST RESPONSE TO INFLIXIMAB. Case report
by: Ivaylo Vazharov, et al.
Published: (2016) -
Ustekinumab in pediatric patients with Crohn's disease: safety, and efficacy results from a multicenter retrospective study in China
by: Ping Li, et al.
Published: (2024) -
Metastatic Crohn's disease despite infliximab therapy
by: Sara Campos, et al.
Published: (2017) -
New Frontiers in Gut Nutrient Sensor Research: Luminal Glutamate-Sensing Cells in Rat Gastric Mucosa
by: Eiji Nakamura, et al.
Published: (2010)